论文部分内容阅读
目的探讨GALECTIN-3基因在胃癌腹膜转移中的作用。方法通过实时定量RT-PCR方法,对35例同期伴腹膜转移病人的胃癌原发灶、淋巴结转移灶、腹膜转移灶、正常胃粘膜组织中GALECTIN-3MRNA的表达水平进行实时定量RT-PCR检测。结果胃癌原发灶(385.639±98.534)、腹膜转移灶(368.589±93.431)、淋巴结转移灶(375.920±94.346)中GALECTIN-3MRNA表达量同正常胃粘膜(2.158±0.896)中的表达量相比,差异具有统计学意义(P<0.05),胃癌原发灶、腹膜转移灶及淋巴结转移灶三者中的表达量两两相比,差异无统计学意义(P>0.05)。GALECTIN-3MRNA在胃癌原发灶与腹膜转移灶中的表达呈正相关(R=0.997,P=0.000)。结论GALECTIN-3MRNA在胃癌中的高表达与胃癌腹膜转移密切相关。胃癌病灶的GALECTIN-3MRNA检测可作为术前判断胃癌已伴腹膜转移或具有腹膜转移潜能的生物学标记。
Objective To investigate the role of GALECTIN-3 in peritoneal metastasis of gastric cancer. Methods Real-time quantitative RT-PCR was used to detect the expression level of GALECTIN-3MRNA in 35 primary gastric cancer patients with peritoneal metastasis, lymph node metastasis, peritoneal metastasis and normal gastric mucosa by real-time quantitative RT-PCR. Results Compared with normal gastric mucosa (2.158 ± 0.896), the expression of GALECTIN-3MRNA in primary gastric cancer (385.639 ± 98.534), peritoneal metastasis (368.589 ± 93.431) and lymph node metastasis (375.920 ± 94.346) The difference was statistically significant (P <0.05). There was no significant difference in the expression of all the three markers between primary gastric cancer, peritoneal metastasis and lymph node metastasis (P> 0.05). The positive expression of GALECTIN-3MRNA in primary gastric cancer and peritoneal metastasis (R = 0.997, P = 0.000). Conclusion The high expression of GALECTIN-3MRNA in gastric cancer is closely related to the peritoneal metastasis of gastric cancer. Gastric cancer lesions GALECTIN-3MRNA detection can be used as a preoperative judgment of gastric cancer has been associated with peritoneal metastasis or have the potential of peritoneal metastasis of biological markers.